ProCE Banner Activity

Efficacy of Selective RET Inhibitors in RET-Driven NSCLC and Thyroid Cancer: A Resource for Clinicians

PDF
Download this PDF resource for a quick overview of the efficacy data for pralsetinib and selpercatinib in RET fusion–positive NSCLC, RET fusion–positive thyroid cancer, and RET mutation–positive medullary thyroid cancer, along with a look at ongoing clinical trials.

Released: January 21, 2021

Expiration: January 20, 2022

Share

Provided by

Provided by Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by an educational grant from

Lilly